secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001493152-22-006230
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 5.03, 3.1, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics secures exclusive DBM supply from MTF for rhNELL-1 spine fusion product
--------------------------------------------------------------------------------

- Exclusive supply agreement with MTF Biologics for demineralized bone matrix (DBM) as carrier for rhNELL-1 bone graft substitute.
- DBM will supply planned 30-patient pilot study and subsequent U.S. pivotal study in spine fusion.
- Five-year term with extension option; targeting the $3 billion spine fusion market.
- Also amended bylaws: stockholders with 15% voting power can call special meetings; exclusive Delaware forum for certain actions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315222006230/0001493152-22-006230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315222006230/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-006230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer